Former Medical Director of the Heart Failure and Cardiac Transplant Program at Massachusetts General Hospital to Lead Clinical Development SOUTH SAN FRANCISCO, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Marc Semigran, M.D., has joined the Company as chief medical officer. In his new position, Dr. Semigran will oversee clinical development and lead MyoKardia's clinical trial strategy. "We are excited to welcome Marc to MyoKardia as chief medical officer," said Tassos Gianakakos, chief executive officer. "His extraordinary medical and scientific expertise and strong relationships in the cardiovascular and clinical communities will be invaluable as MyoKardia pursues its mission to change the world for patients with serious cardiovascular disease through bold and innovative science." "Dr. Semigran shares MyoKardia's values, particularly with respect to Patients First and Passion for Science, and I am confident his leadership will enable MyoKardia to deliver first-ever, potentially transformative therapies for patients with heritable cardiomyopathies," said Mr. Gianakakos. Most recently, Dr. Semigran led the Massachusetts General Hospital Heart Failure and Cardiac Transplant Program as section head and medical director, from 2004 to 2016. In addition, he was principal investigator of the Harvard Regional Clinical Center of the National Heart, Lung, and Blood Institute Heart Failure Network. Dr. Semigran has been a member of the internal medicine and cardiology staff of Massachusetts General for more than 25 years and is an associate professor at Harvard Medical School. "MyoKardia is a great innovator in cardiovascular therapy, and the Company is emblematic of the science-driven, precision medicine approach that will bring about much-needed therapies for patients," said Dr. Semigran. "I am delighted to have the opportunity to lead MyoKardia's clinical programs at such a pivotal time for the Company."